Business, energy, technology, markets and global industry news from Business News Today

VANFLYTA

PharmaDeviceNews VANFLYTA
Psoriasis treatment innovation moves closer to market as the US Food and Drug Administration grants Priority Review to Takeda’s zasocitinib following positive Phase 3 trial results, including head-to-head superiority over deucravacitinib in plaque psoriasis. Representative image.
Pharma & Biotech

Innovent just secured seven reimbursement wins in China. Can mazdutide deliver its next growth surge?

Innovent gains China reimbursement for seven medicines, including mazdutide and PECONDLE. See how access could shape growth in 2027.

Read More
Innovent Biologics and Daiichi Sankyo’s VANFLYTA commercialization agreement puts China’s newly diagnosed FLT3-ITD-positive acute myeloid leukemia market in focus as the partners move from regulatory approval toward wider clinical adoption. Representative image.
Pharma & Biotech

What Innovent Biologics’ VANFLYTA deal means for FLT3-ITD AML treatment in China

Innovent Biologics will commercialize Daiichi Sankyo’s VANFLYTA in China after its June approval for newly diagnosed FLT3-ITD AML.

Read More